213 related articles for article (PubMed ID: 28697809)
1. Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users.
Jamalidoust M; Namayandeh M; Moghadami M; Ziyaeyan M
Virol J; 2017 Jul; 14(1):127. PubMed ID: 28697809
[TBL] [Abstract][Full Text] [Related]
2. HCV genotype analysis in HCV-HIV-co-infected Puerto Ricans who are injecting drug users: undetermined and mixed infections.
Ríos-Olivares E; Yamamura Y; Gómez MA; Guzmán L; Rodríguez N; Fernández D; Hunter Mellado R
Cell Mol Biol (Noisy-le-grand); 2001 Sep; 47(6):1017-24. PubMed ID: 11785651
[TBL] [Abstract][Full Text] [Related]
3. Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes.
Behzadpour D; Ahmadi Vasmehjani A; Mousavi Nasab SD; Ahmadi NA; Baharlou R
Pathog Glob Health; 2016; 110(7-8):310-315. PubMed ID: 27830997
[TBL] [Abstract][Full Text] [Related]
4. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
[TBL] [Abstract][Full Text] [Related]
5. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
6. Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patients.
Nilsson J; Weiland O
Scand J Infect Dis; 2010 Jul; 42(6-7):533-9. PubMed ID: 20214543
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
Sulkowski M; Hezode C; Gerstoft J; Vierling JM; Mallolas J; Pol S; Kugelmas M; Murillo A; Weis N; Nahass R; Shibolet O; Serfaty L; Bourliere M; DeJesus E; Zuckerman E; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
Lancet; 2015 Mar; 385(9973):1087-97. PubMed ID: 25467560
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of chronic hepatitis C in human immunodeficiency virus infected patients].
Begovac J; Romih V
Acta Med Croatica; 2009 Dec; 63(5):423-9. PubMed ID: 20198902
[TBL] [Abstract][Full Text] [Related]
9. [The prevalence of hepatitis C virus (HCV) subtypes in Chinese HIV-1/HCV co-infected individuals].
Liu J; Yang Y; Gong JL; Zhang ZN; Zhang M; Wang YN; Jiang YJ; Qi ZT; Pan QC; Zhong P; Shang H
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Jul; 30(7):663-7. PubMed ID: 19957585
[TBL] [Abstract][Full Text] [Related]
10. Factors related to the chronicity and evolution of hepatitis C infection in patients co-infected by the human immunodeficiency virus.
Pérez-Cano R; Fernández-Gutiérrez C; López-Suárez A; Mira J; Girón-González JA
Clin Microbiol Infect; 2002 Sep; 8(9):589-97. PubMed ID: 12427219
[TBL] [Abstract][Full Text] [Related]
11. Higher levels of hepatitis C virus RNA found in blood donors co-infected with HIV as compared to HCV mono-infected donors.
Alidjinou EK; Moukassa D; Ebatetou-Ataboho E; Mahoungou GH; Pambou JP; Sané F; Prevost B; Bocket L; Ibara JR; Hober D
J Infect Dev Ctries; 2014 Aug; 8(8):1068-71. PubMed ID: 25116677
[TBL] [Abstract][Full Text] [Related]
12. HCV non-1b genotypes in injecting drug users from Romania.
Ruta S; Sultana C; Oprea C; Vagu C; Ceausu E; Cernescu C
J Infect Dev Ctries; 2016 May; 10(5):523-7. PubMed ID: 27249529
[TBL] [Abstract][Full Text] [Related]
13. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.
Van den Eynde E; Crespo M; Esteban JI; Jardi R; Ribera E; Carbonell J; Rodríguez-Frias F; Falco V; Curran A; Imaz A; Villar del Saz S; Ocaña I; Esteban R; Pahissa A
Clin Infect Dis; 2009 Apr; 48(8):1152-9. PubMed ID: 19275492
[TBL] [Abstract][Full Text] [Related]
14. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?
Rockstroh JK; Peters L; Grint D; Soriano V; Reiss P; Monforte Ad; Beniowski M; Losso MH; Kirk O; Kupfer B; Mocroft A;
J Hepatol; 2013 Aug; 59(2):213-20. PubMed ID: 23583272
[TBL] [Abstract][Full Text] [Related]
15. The distinct epidemic characteristics of HCV co-infection among HIV-1-infected population caused by drug injection and sexual transmission in Yunnan, China.
Zhang AM; Yang M; Gao L; Zhang M; Jiao L; Feng Y; Dong X; Xia X
Epidemiol Infect; 2019 Sep; 147():e261. PubMed ID: 31475647
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of genotype 4 among hepatitis C virus-infected intravenous drug users in north-eastern Poland.
Chlabicz S; Flisiak R; Kowalczuk O; Wiercińska-Drapalo A; Pytel-Krolczuk B; Prokopowicz D; Chyczewski L
J Med Virol; 2008 Apr; 80(4):615-8. PubMed ID: 18297715
[TBL] [Abstract][Full Text] [Related]
17. Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.
Dore GJ; Torriani FJ; Rodriguez-Torres M; Bräu N; Sulkowski M; Lamoglia RS; Tural C; Clumeck N; Nelson MR; Mendes-Correa MC; Godofsky EW; Dieterich DT; Yetzer E; Lissen E; Cooper DA
AIDS; 2007 Jul; 21(12):1555-9. PubMed ID: 17630550
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus populations in the plasma, peripheral blood mononuclear cells and cerebrospinal fluid of HIV/hepatitis C virus-co-infected patients.
Bagaglio S; Cinque P; Racca S; Pedale R; Grasso MA; Lazzarin A; Morsica G
AIDS; 2005 Oct; 19 Suppl 3():S151-65. PubMed ID: 16251813
[TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
[TBL] [Abstract][Full Text] [Related]
20. High prevalence of occult hepatitis C virus infection in injection drug users with HIV infection.
Donyavi T; Bokharaei-Salim F; Khanaliha K; Sheikh M; Bastani MN; Moradi N; Babaei R; Habib Z; Fakhim A; Esghaei M
Arch Virol; 2019 Oct; 164(10):2493-2504. PubMed ID: 31346769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
